Dr. Reddy’s entered into with Gilead license agreement in relation to the registration, manufacture, and sale of a medicinal product of ramdevpir, which is currently being considered as a potential means of therapy COVID-19. It is reported Bloomberg.
The agreement of the parties extends to 127 countries. After the transfer of the production of Dr. Reddy’s will be responsible for the increase in the production of the drug and ensuring the registration process in each country.
Currently ramdevpir approved in the USA for the treatment of COVID-19 in an emergency situation. The drug also is approved for this indication in the EU.